Vanessa K. Favasuli

Candiolo, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.

Journal: Blood
Published: February 25, 2026

A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

A first-in-class RNA degrader reduces c-MYC expression and myeloma cell survival in preclinical models.

Journal: Blood
Published: January 22, 2026

CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

Journal: Blood
Published: February 05, 2025

Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.

Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 17, 2024

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma.

Journal: Blood
Published: October 04, 2023

DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification.

DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification.

Journal: Haematologica
Published: April 04, 2023

Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma.

Expression levels of NONO, a nuclear protein primarily involved in paraspeckles function, are associated with several deregulated molecular pathways and poor clinical outcome in multiple myeloma.

Journal: Discover oncology
Published: July 16, 2022

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins.

Activation of long non-coding RNA NEAT1 leads to survival advantage of multiple myeloma cells by supporting a positive regulatory loop with DNA repair proteins.

Journal: Haematologica
Published: March 31, 2022

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma.

Dissecting the Biological Relevance and Clinical Impact of lncRNA MIAT in Multiple Myeloma.

Journal: Cancers
Published: September 29, 2021

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity.

Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity.

Journal: Cancers
Published: September 09, 2021

In Vitro Silencing of lncRNAs Using LNA GapmeRs.

In Vitro Silencing of lncRNAs Using LNA GapmeRs.

Journal: Methods in molecular biology (Clifton, N.J.)
Published: June 23, 2021

Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.

Genomic Instability in Multiple Myeloma: A "Non-Coding RNA" Perspective.

Journal: Cancers
Published: March 22, 2021
Showing 1-12 of 20

Last Updated: 09/26/2026